FDA approves leucovorin calcium as first treatment for CFD-FOLR1

Signal

The U.S. Food and Drug Administration approved an expanded indication for Wellcovorin (leucovorin calcium) tablets covering the treatment of cerebral folate deficiency in adult and pediatric patients who carry a confirmed variant in the folate receptor 1 gene (CFD-FOLR1). The agency announced the decision in 2025. This marks the first FDA-approved treatment specifically indicated for CFD-FOLR1, a rare inherited neurological disorder in which defective folate transport across the blood-brain barrier leads to progressive neurological deterioration.

Why it matters

CFD-FOLR1 is an ultra-rare condition with no previously approved therapy, meaning clinicians had no labeled treatment option and payers had no established coverage framework. The approval gives prescribers a formally sanctioned treatment pathway and, critically, provides a regulatory hook for payers to build coverage policies around a defined genetic criterion - confirmed FOLR1 variant - rather than relying on case-by-case medical necessity arguments. Because leucovorin calcium is a long-established generic agent used in oncology supportive care, the supply chain is mature, but the new rare-disease indication may support distinct access and reimbursement dynamics relative to its existing uses. Genetic confirmation as a gating criterion also reinforces the diagnostic requirement, raising the profile of FOLR1 variant testing in the workup of unexplained pediatric neurological regression.

What we are watching

The next observable indicators are payer coverage policy issuances - particularly from large commercial insurers and Medicaid managed care organizations - that define how genetic confirmation requirements will be operationalized for prior authorization. Also worth tracking: whether the approval accelerates newborn or early-childhood screening discussions for FOLR1 variants in rare-disease advocacy and policy channels, and whether any sponsor pursues orphan drug designation or seeks to formalize a branded rare-disease product around this indication now that a clinical pathway is established.